POSITIVE RESULTS

CervoMed's 80mg neflamapimod hits safety goal in small open-label DLB study

The 26-patient Phase 2 trial met its safety and pharmacokinetic objectives, but the company's own Phase 2b trial had already failed to replicate earlier cognitive benefit data in this same drug program.

By AppliedXLJuly 14, 2026Trial NCT06815965

Executive Summary

CervoMed's newest neflamapimod study met its safety, tolerability, and pharmacokinetic goals, clearing an operational bar rather than an efficacy one.
The company is using this pharmacokinetic result to justify the dose it has chosen for its next controlled trial, after its larger placebo-controlled study in the same indication fell short on the endpoint that mattered most.
The sponsor's presentation frames plasma drug levels as the fix for its prior trial's disappointing result, a causal explanation that the exploratory analyses support but that a controlled trial has not yet confirmed.
No other program targeting this same kinase is being tested in this indication, so the near-term evidence on whether the mechanism works in Lewy body dementia rests entirely on this company's own trials.

The disclosure

CervoMed disclosed results on July 14, 2026, from NCT06815965, a 24-week, open-label Phase 2 study of neflamapimod 80 mg BID in 26 patients with probable dementia with Lewy bodies (DLB). The trial's four primary endpoints covered safety and tolerability alongside trough (Ctrough) and maximum (Cmax) plasma concentration measures, not a cognitive or functional efficacy endpoint. The company said the regimen was well tolerated and achieved target trough concentrations, with what it called encouraging but descriptive secondary signals of stabilization in executive function and global cognition. NCT06815965+1

Probability of Success

Endpoint Met11%

Completes95%

Clinical Significance21%

Regulatory59%

Why the dose matters

CervoMed's chief executive, John Alam, said the analyses presented at the Alzheimer's Association International Conference "provide consistent evidence across clinical, plasma biomarker, and imaging studies that neflamapimod has the potential to address the underlying cause of DLB". The company said it has selected 50 mg TID as its planned Phase 3 dose and cited alignment with the FDA, EMA, MHRA, and PMDA on that program. That dose decision follows directly from the pharmacokinetic problem the company says undermined its prior pivotal-stage trial. CervoMed

The prior miss

In the placebo-controlled phase of CervoMed's 159-patient Phase 2b RewinD-LB trial, neflamapimod did not replicate the improvement on the Clinical Dementia Rating-Sum of Boxes scale that an earlier Phase 2a study had shown against placebo. The company attributes that result to two factors: a higher-than-targeted share of patients with Alzheimer's co-pathology, and a drug batch that did not reach expected plasma concentrations. Exploratory analyses of that trial found a treatment effect favoring neflamapimod in patients with lower plasma pTau181 levels and in those who achieved the intended drug exposure, but those are exploratory, not the trial's confirmed primary result. CervoMed

Registry signals

The trial's primary completion date moved from December 2025 to March 2026 and its enrollment target rose from 20 to 26 patients, changes the operational model characterizes as within the routine band for this design. The study moved from Recruiting to Active, not recruiting in October 2025 at the close of enrollment, then to Completed in April 2026, the normal sequence for a trial that filled to target. The company's own disclosure of results landed 195 days after the Q4 2025 window it had guided to in three separate updates between March and August 2025. NCT06815965+1

The competitive frame

No other industry-sponsored trial is currently testing a MAPK14 inhibitor in dementia with Lewy bodies; the closest peer sharing both the target and mechanism class is Neurokine Therapeutics' MW150, tested in Alzheimer's disease rather than DLB. The nearest DLB-specific comparators, including donepezil, pimavanserin, and intepirdine, work through different targets entirely. With no validated disease-modifying mechanism established in DLB and no direct competitor on this target in this indication, the evidence base for whether p38 MAP kinase inhibition changes disease course in Lewy body dementia rests on CervoMed's own trial program.

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.